Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track TRAW with free AI briefings, catalyst countdowns, and dilution alerts.

TRAW · Traws Pharma, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$5M Cash on Hand
3mo Cash Runway
Follow TRAW by email Get an email when TRAW reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about TRAW, unsubscribe in one click. Privacy

📣 What TRAW Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Any approved or standard-of-care therapy Myelodysplastic Syndrome Phase 3 · NCT02562443 Terminated
Rigosertib Sodium Myelodysplastic Syndromes Phase 3 · NCT01928537 Completed
Rigosertib Myelodysplastic Syndrome Phase 3 · NCT02562443 Terminated
ON 01910.Na Concentrate Myelodysplastic Syndrome Phase 1/2 · NCT00867061 Withdrawn
TRX-100 Influenza Phase 2 · NCT07371650 Active not recruiting
Ratutrelvir (83-0060) non-randomised COVID - 19 Phase 2 · NCT07157007 Completed
Ratutrelvir COVID - 19 Phase 2 · NCT07157007 Completed
Narazaciclib (ON123300) Endometrioid Endometrial Cancer Phase 1/2 · NCT05705505 Unknown
Influenza A/France/759/2021 (H1N1) virus Influenza Phase 2 · NCT07503405 Not yet recruiting
Briciclib Sodium (ON 013105) Lymphoma Phase 1 · NCT01049113 Terminated
Irinotecan Hepatoma Phase 1 · NCT00861783 Completed
83-0060 Healthy Volunteers Only Phase 1 · NCT06402136 Completed
Briciclib Neoplasms Phase 1 · NCT02168725 Terminated

Also used in these trials (approved or third-party drugs, not TRAW's own candidates): Gemcitabine Hydrochloride, Azacitidine, Nirmatrelvir And Ritonavir, Nivolumab, Letrozole, Cisplatin.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

TRAW holds $5M in cash and short-term investments (as of Jun 30, 2026) and burns about $5M/quarter from operations, an estimated runway of 3 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 90 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when TRAW files for a raise →

👥 Who Owns TRAW

Insiders 12.4% Institutions 59.2% Public and other holders 28.4%
HolderTypeShares% of sharesAs of
Sirenia Capital Management LP Institution (13G, 5%+) 6,565,474 42.72% 2026-06-30
Ikarian Capital, LLC Institution (13G, 5%+) 1,555,423 10.12% 2026-06-30
ORBIMED ADVISORS LLC
10% owner · +2.99M options
Insider 1,203,250 7.83% 2026-04-16
Perceptive Advisors LLC Institution (13G, 5%+) 979,815 6.38% 2026-03-31
Iain D. Dukes
Chief Executive Officer, Director · +717,946 options
Insider 171,130 1.11% 2025-12-12
Nikolay Savchuk
Chief Operating Officer, Director · +278,010 options
Insider 150,606 0.98% 2025-12-12
Charles David Pauza
Chief Science Officer Virology · +321,659 options
Insider 115,971 0.75% 2025-12-12
Robert Redfield
Chief Medical Officer · +290,936 options
Insider 113,919 0.74% 2025-12-12
Werner Cautreels
Director · +76,434 options
Insider 109,222 0.71% 2025-12-12
Charles Nolan Parker
Chief Financial Officer · +288,521 options
Insider 15,393 0.10% 2025-10-12
Mary Teresa Shoemaker
Director · +83,744 options
Insider 6,292 0.04% 2025-12-12
Jack E Stover
Director · +83,744 options
Insider 6,165 0.04% 2025-12-12

Share count 15,368,277 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full TRAW picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TRAW and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.